Related Experiment Video
Updated: Apr 7, 2026

Transcutaneous Assessment of Renal Function in Conscious Rodents
Published on: March 26, 2016
Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy
Susan J Lewis1, Lynn A Switaj, Bruce A Mueller
1Department of Clinical, Social and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, USA.
Background/Aims:
To study transmembrane clearance (CLTM) and adsorption of tedizolid, a novel oxazolidinone antibiotic, in continuous hemofiltration (CVVH) and continuous hemodialysis (CVVHD).
Methods:
In vitro CVVH/CVVHD models with polysulfone and AN69 hemodiafilters were used. Tedizolid CLTM during CVVH/CVVHD was assessed at various ultrafiltrate (Quf) and dialysate rates (Qd). Tedizolid adsorption was tested in a recirculating CVVH model over 4 h.
Results:
In CVVH, CLTM did not differ between filter types. In CVVHD, tedizolid CLTM was significantly higher with the polysulfone hemodiafilter at Qd 6 l/h (p < 0.02). Tedizolid exhibited irreversible adsorption to the CRRT apparatus and bound significantly higher to the polysulfone hemodiafilter.
Conclusion:
Tedizolid's CLTM is dependent on Qd, Quf, and hemodiafilter type. At conventional CRRT rates, tedizolid CLTM appears modest relative to total body clearance and is unlikely to require dose adjustments. CRRT adsorption in the clinical setting is likely less than what we observed in this in vitro, continuously recirculating blood model.
More Related Videos
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Renal Drug Excretion: Tubular Reabsorption

